Targeting RAS–RAF–MEK–ERK signaling pathway in human cancer: Current status in clinical trials

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989 · see citing works

Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review

Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,314 · see citing works

Mutations of the BRAF gene in human cancer

Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674 · see citing works

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449 · see citing works

Mammalian MAP kinase signalling cascades

Chang, L., & Karin, M. (2001) · Nature · doi:10.1038/35065000 · Cited by 5,118 · see citing works

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

Rittmeyer, A., Barlési, F., Waterkamp, D., Park, K., Ciardiello, F., von Pawel, J., Gadgeel, S. M., Hida, T., Kowalski, D. M., Cobo, M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)32517-x · Cited by 4,684 · see citing works

Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF

Wan, P., Garnett, M. J., Roe, S. M., Lee, S., Niculescu‐Duvaz, D., Good, V. M., Cancer Genome Project, Jones, C. M., Marshall, C. J., Springer, C. J., et al. (2004) · Cell · doi:10.1016/s0092-8674(04)00215-6 · Cited by 2,799 · see citing works

K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions

Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557 · see citing works

The Clinical KRAS(G12C) Inhibitor AMG 510 Drives Anti-Tumour Immunity

Canon, J., Rex, K., Saiki, A. Y., Mohr, C., Cooke, K., Bagal, D., Gaida, K., Holt, T., Knutson, C. G., Koppada, N., et al. (2019) · Nature · doi:10.1038/s41586-019-1694-1 · Cited by 2,277 · see citing works

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

Nazarian, R., Shi, H., Wang, Q., Kong, X., Koya, R. C., Lee, H., Chen, Z., Lee, M., Attar, N., Sazegar, H., et al. (2010) · Nature · doi:10.1038/nature09626 · Cited by 2,177 · see citing works

Combined Vemurafenib and Cobimetinib in BRAF -Mutated Melanoma

Larkin, J., Ascierto, P. A., Dréno, B., Atkinson, V. G., Liszkay, G., Maio, M., Mandalà, M., Демидов, Л. В., Stroyakovskiy, D., Thomas, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408868 · Cited by 2,062 · see citing works

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR

Prahallad, A., Sun, C., Huang, S., Di Nicolantonio, F., Salazar, R., Zecchin, D., Beijersbergen, R. L., Bardelli, A., & Bernards, R. (2012) · Nature · doi:10.1038/nature10868 · Cited by 2,051 · see citing works

RAS Proteins and Their Regulators in Human Disease

Simanshu, D. K., Nissley, D. V., & McCormick, F. (2017) · Cell · doi:10.1016/j.cell.2017.06.009 · Cited by 1,943 · see citing works

Signaling pathway of MAPK/ERK in cell proliferation, differentiation, migration, senescence and apoptosis

Sun, Y., Liu, W., Liu, T., Xu, F., Yang, N., & Zhou, H. (2015) · Journal of Receptors and Signal Transduction · doi:10.3109/10799893.2015.1030412 · Cited by 1,830 · see citing works

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

Poulikakos, P. I., Zhang, C., Bollag, G. E., Shokat, K. M., & Rosen, N. X. (2010) · Nature · doi:10.1038/nature08902 · Cited by 1,818 · see citing works

Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion

Straussman, R., Morikawa, T., Shee, K., Barzily-Rokni, M., Qian, Z. R., Du, J., Davis, A., Mongare, M. M., Gould, J., Frederick, D. T., et al. (2012) · Nature · doi:10.1038/nature11183 · Cited by 1,771 · see citing works

Targeting PI3K in cancer: mechanisms and advances in clinical trials

Yang, J., Nie, J., Ma, X., Wei, Y., Peng, Y., & Wei, X. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0954-x · Cited by 1,540 · see citing works

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

Johannessen, C. M., Boehm, J. S., Kim, S. Y., Thomas, S. R., Wardwell, L., Johnson, L. A., Emery, C. M., Stransky, N., Cogdill, A. P., Barretina, J., et al. (2010) · Nature · doi:10.1038/nature09627 · Cited by 1,460 · see citing works

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)

Poulikakos, P. I., Persaud, Y., Janakiraman, M., Kong, X., Ng, C., Moriceau, G., Shi, H., Atefi, M., Titz, B., Gabay, M. T., et al. (2011) · Nature · doi:10.1038/nature10662 · Cited by 1,454 · see citing works

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

Tsai, J., Lee, J. T., Wang, W., Zhang, J., Cho, H., Mamo, S., Bremer, R., Gillette, S., Kong, J., Haass, N. K., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711741105 · Cited by 1,346 · see citing works

The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients

Hallin, J., Engstrom, L. D., Hargis, L., Calinisan, A., Aranda, R., Briere, D. M., Sudhakar, N., Bowcut, V., Baer, B. R., Ballard, J. A., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1167 · Cited by 1,304 · see citing works

Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K

Villanueva, J., Vultur, A., Lee, J. T., Somasundaram, R., Fukunaga‐Kalabis, M., Cipolla, A. K., Wubbenhorst, B. S., Xu, X., Gimotty, P. A., Kee, D., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.11.023 · Cited by 1,250 · see citing works

Acquired Resistance to KRAS ^G12C Inhibition in Cancer

Awad, M. M., Liu, S., Rybkin, I. I., Arbour, K. C., Dilly, J., Zhu, V. W., Johnson, M. L., Heist, R. S., Patil, T., Riely, G. J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2105281 · Cited by 1,247 · see citing works

Regulation of the mTOR Complex 1 Pathway by Nutrients, Growth Factors, and Stress

Sengupta, S., Peterson, T. R., & Sabatini, D. M. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.09.026 · Cited by 1,234 · see citing works

The MAPK signalling pathways and colorectal cancer

Fang, J. Y., & Richardson, B. C. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70168-6 · Cited by 1,185 · see citing works

Targeting KRAS mutant cancers with a covalent G12C-specific inhibitor

Janes, M. R., Zhang, J., Li, L.-S., Hansen, R., Peters, U., Guo, X., Chen, Y., Babbar, A., Firdaus, S. J., Darjania, L., et al. (2018) · Cell · doi:10.1016/j.cell.2018.01.006 · Cited by 1,172 · see citing works

Targeting RAS–ERK signalling in cancer: promises and challenges

Samatar, A. A., & Poulikakos, P. I. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4281 · Cited by 1,163 · see citing works

RAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors

Su, F., Virós, A., Milagre, C. S., Trunzer, K., Bollag, G. E., Spleiss, O., Reis-Filho, J. S., Kong, X., Koya, R. C., Flaherty, K. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1105358 · Cited by 1,038 · see citing works

EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of <i>BRAF</i> -Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib

Corcoran, R. B., Ebi, H., Turke, A. B., Coffee, E. M., Nishino, M., Cogdill, A. P., Brown, R. D., Della Pelle, P., Dias-Santagata, D., Hung, K. E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0341 · Cited by 1,022 · see citing works

Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy

Shi, H., Hugo, W., Kong, X., Hong, A., Koya, R. C., Moriceau, G., Chodon, T., Guo, R., Johnson, D. B., Dahlman, K. B., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0642 · Cited by 982 · see citing works

The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma

Allen, E. M. V., Wagle, N., Sucker, A., Treacy, D. J., Johannessen, C. M., Goetz, E. M., Place, C. S., Taylor-Weiner, A. N., Whittaker, S. R., Kryukov, G. V., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0617 · Cited by 904 · see citing works

The role of BRAF V600 mutation in melanoma

Ascierto, P. A., Kirkwood, J. M., Grob, J., Simeone, E., Grimaldi, A. M., Maio, M., Palmieri, G., Testori, A., Marincola, F. M., & Mozzillo, N. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-85 · Cited by 804 · see citing works

Selective inhibition of oncogenic KRAS output with small molecules targeting the inactive state

Patricelli, M. P., Janes, M. R., Li, L.-S., Hansen, R., Peters, U., Kessler, L. V., Chen, Y., Kucharski, J. M., Feng, J., Ely, T., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1105 · Cited by 759 · see citing works

Dual-specificity phosphatases: critical regulators with diverse cellular targets

Patterson, K. I., Brummer, T., O'brien, P. M., & Daly, R. J. (2009) · Biochemical Journal · doi:10.1042/bj20082234 · Cited by 744 · see citing works

MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade.

Ebert, P. J. R., Cheung, J., Yang, Y., McNamara, E., Hong, R., Moskalenko, M., Gould, S. E., Maecker, H., Irving, B. A., Kim, J. M., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.01.024 · Cited by 713 · see citing works

Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer

Bryant, K. L., Stalnecker, C. A., Zeitouni, D., Klomp, J. E., Peng, S., Tikunov, A. P., Gunda, V., Pierobon, M., Waters, A. M., George, S. D., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0368-8 · Cited by 692 · see citing works

Regulation of Raf-1 by direct feedback phosphorylation.

Dougherty, M., Müller, J., Ritt, D. A., Zhou, M., Zhou, X.-Z., Copeland, T., Conrads, T., Veenstra, T., Lu, K., & Morrison, D. (2005) · Molecules and Cells · doi:10.1016/j.molcel.2004.11.055 · Cited by 663 · see citing works

MEK1 mutations confer resistance to MEK and B-RAF inhibition

Emery, C. M., Vijayendran, K. G., Zipser, M. C., Sawyer, A. M., Niu, L., Kim, J. J., Hatton, C., Chopra, R., Oberholzer, P. A., Karpova, M. B., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905833106 · Cited by 642 · see citing works

Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers

Kinsey, C. G., Camolotto, S. A., Boespflug, A. M., Guillen, K. P., Foth, M., Truong, A., Schuman, S. S., Shea, J. E., Seipp, M. T., Yap, J. T., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0367-9 · Cited by 634 · see citing works

Small molecules, big impact: 20 years of targeted therapy in oncology

Bedard, P. L., Hyman, D. M., Davids, M. S., & Siu, L. L. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30164-1 · Cited by 616 · see citing works

Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance

Hugo, W., Shi, H., Sun, L., Piva, M., Song, C., Kong, X., Moriceau, G., Hong, A., Dahlman, K. B., Johnson, D. B., et al. (2015) · Cell · doi:10.1016/j.cell.2015.07.061 · Cited by 596 · see citing works

GSK1120212 (JTP-74057) Is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained In Vivo Pathway Inhibition

Gilmartin, A. G., Bleam, M. R., Groy, A., Moss, K. G., Minthorn, E. A., Kulkarni, S. G., Rominger, C. M., Erskine, S. G., Fisher, K. E., Yang, J., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2200 · Cited by 590 · see citing works

p70S6 kinase signals cell survival as well as growth, inactivating the pro-apoptotic molecule BAD

Harada, H., Andersen, J., Mann, M., Terada, N., & Korsmeyer, S. (2001) · Proceedings of the National Academy of Sciences of the United States of America · doi:10.1073/pnas.171301998 · Cited by 563 · see citing works

Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells

Lee, H.-J., Zhuang, G., Cao, Y., Du, P., Kim, H.-J., & Settleman, J. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.05.019 · Cited by 555 · see citing works

The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies

Lin, L., Sabnis, A. J., Chan, E., Olivas, V., Cade, L., Pazarentzos, E., Asthana, S., Neel, D., Yan, J. J., Lu, X., et al. (2015) · Nature Genetics · doi:10.1038/ng.3218 · Cited by 551 · see citing works

PTEN Loss Confers BRAF Inhibitor Resistance to Melanoma Cells through the Suppression of BIM Expression

Paraiso, K. H. T., Xiang, Y., Rebecca, V. W., Abel, E. V., Chen, Y. A., Munko, A. C., Wood, E. R., Smalley, I., Sondak, V. K., Anderson, A. R. A., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2954 · Cited by 545 · see citing works

RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors

Loi, S., Dushyanthen, S., Beavis, P. A., Salgado, R., Denkert, C., Savas, P., Combs, S., Rimm, D. L., Giltnane, J. M., Estrada, M. V., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1125 · Cited by 536 · see citing works

Targeting the MAPK pathway in KRAS-driven tumors

Drosten, M., & Barbacid, M. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.013 · Cited by 512 · see citing works

Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial

Dummer, R., Schadendorf, D., Ascierto, P. A., Arance, A. M., Dutriaux, C., Giacomo, A. M. D., Rutkowski, P. L., Vecchio, M. D., Gutzmer, R., Mandalà, M., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30180-8 · Cited by 501 · see citing works

The MAPK and AMPK signalings: interplay and implication in targeted cancer therapy

Yuan, J., Dong, X., Yap, J., & Hu, J. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00949-4 · Cited by 500 · see citing works

A dimerization-dependent mechanism drives RAF catalytic activation

Rajakulendran, T., Sahmi, M., Lefrançois, M., Sicheri, F., & Therrien, M. (2009) · Nature · doi:10.1038/nature08314 · Cited by 490 · see citing works

Tumour cell survival signalling by the ERK1/2 pathway

Balmanno, K., & Cook, S. J. (2009) · Cell Death &amp; Differentiation · doi:10.1038/cdd.2008.148 · Cited by 484 · see citing works

MAP Kinase Pathway Alterations in <i>BRAF</i> -Mutant Melanoma Patients with Acquired Resistance to Combined RAF/MEK Inhibition

Wagle, N., Van Allen, E. M., Treacy, D. J., Frederick, D. T., Cooper, Z. A., Taylor-Weiner, A., Rosenberg, M., Goetz, E. M., Sullivan, R. J., Farlow, D. N., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0631 · Cited by 478 · see citing works

Targeting ER stress–induced autophagy overcomes BRAF inhibitor resistance in melanoma

Ma, X.-H., Piao, S.-F., Dey, S., Mcafee, Q., Karakousis, G., Villanueva, J., Hart, L. S., Levi, S., Hu, J., Zhang, G., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci70454 · Cited by 457 · see citing works

Targeting ERK, an Achilles' Heel of the MAPK pathway, in cancer therapy

Liu, F., Yang, X., Geng, M., & Huang, M. (2018) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2018.01.008 · Cited by 434 · see citing works

MED12 Controls the Response to Multiple Cancer Drugs through Regulation of TGF-β Receptor Signaling

Huang, S., Hölzel, M., Knijnenburg, T., Schlicker, A., Roepman, P., McDermott, U., Garnett, M., Grernrum, W., Sun, C., Prahallad, A., et al. (2012) · Cell · doi:10.1016/j.cell.2012.10.035 · Cited by 430 · see citing works

Wild-Type and Mutant B-RAF Activate C-RAF through Distinct Mechanisms Involving Heterodimerization

Garnett, M. J., Rana, S., Paterson, H., Barford, D., & Marais, R. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.10.022 · Cited by 416 · see citing works

The clinical development of MEK inhibitors

Zhao, Y., & Adjei, A. A. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.83 · Cited by 403 · see citing works

A combinatorial strategy for treating KRAS-mutant lung cancer

Manchado, E., Weissmueller, S., Morris, J. P., Chen, C.-C., Wullenkord, R., Lujambio, A., de Stanchina, E., Poirier, J. T., Gainor, J. F., Corcoran, R. B., et al. (2016) · Nature · doi:10.1038/nature18600 · Cited by 403 · see citing works

Relief of Feedback Inhibition of <i>HER3</i> Transcription by RAF and MEK Inhibitors Attenuates Their Antitumor Effects in <i>BRAF</i> -Mutant Thyroid Carcinomas

Montero-Conde, C., Ruiz-Llorente, S., Dominguez, J. M., Knauf, J. A., Viale, A., Sherman, E. J., Ryder, M., Ghossein, R. A., Rosen, N., & Fagin, J. A. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0531 · Cited by 382 · see citing works

Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma

Long, G. V., Fung, C., Menzies, A. M., Pupo, G. M., Carlino, M. S., Hyman, J., Shahheydari, H., Tembe, V., Thompson, J. F., Saw, R. P., et al. (2014) · Nature Communications · doi:10.1038/ncomms6694 · Cited by 375 · see citing works

Resistance to BRAF-targeted therapy in melanoma

Sullivan, R. J., & Flaherty, K. T. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2012.11.019 · Cited by 373 · see citing works

A molecular assembly phase transition and kinetic proofreading modulate Ras activation by SOS

Huang, W. Y. C., Alvarez, S. A., Kondo, Y., Lee, Y. K., Chung, J. K., Lam, H. Y. M., Biswas, K. H., Kuriyan, J., & Groves, J. T. (2019) · Science · doi:10.1126/science.aau5721 · Cited by 352 · see citing works

<i>BRAF</i> Gene Amplification Can Promote Acquired Resistance to MEK Inhibitors in Cancer Cells Harboring the BRAF V600E Mutation

Corcoran, R. B., Dias-Santagata, D., Bergethon, K., Iafrate, A. J., Settleman, J., & Engelman, J. A. (2010) · Science Signaling · doi:10.1126/scisignal.2001148 · Cited by 350 · see citing works

Tunable-Combinatorial Mechanisms of Acquired Resistance Limit the Efficacy of BRAF/MEK Cotargeting but Result in Melanoma Drug Addiction

Moriceau, G., Hugo, W., Hong, A., Shi, H., Kong, X., Yu, C. C., Koya, R. C., Samatar, A. A., Khanlou, N., Braun, J. G., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2014.11.018 · Cited by 345 · see citing works

Myeloid cells are required for PD-1/PD-L1 checkpoint activation and the establishment of an immunosuppressive environment in pancreatic cancer

Zhang, Y., Velez-Delgado, A., Mathew, E., Li, D., Mendez, F., Flannagan, K., Rhim, A. D., Simeone, D. M., Beatty, G. L., & di Magliano, M. P. (2016) · Gut · doi:10.1136/gutjnl-2016-312078 · Cited by 338 · see citing works

Effects of MAPK and PI3K Pathways on PD-L1 Expression in Melanoma

Atefi, M. S., Avramis, E. V., Lassen, A., Wong, D. J. L., Robert, L., Foulad, D. S., Cerniglia, M., Titz, B., Chodon, T., Graeber, T. G., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2797 · Cited by 335 · see citing works

Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms

Johnson, D. B., Menzies, A. M., Zimmer, L., Eroglu, Z., Ye, F., Zhao, S., Rizos, H., Sucker, A., Scolyer, R. A., Gutzmer, R., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.08.022 · Cited by 324 · see citing works

Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers

Hatzivassiliou, G., Haling, J. R., Chen, H., Song, K. W., Price, S., Heald, R. A., Hewitt, J. F. M., Zak, M., Peck, A., Orr, C., et al. (2013) · Nature · doi:10.1038/nature12441 · Cited by 317 · see citing works

SHP2 inhibition prevents adaptive resistance to MEK inhibitors in multiple cancer models

Fedele, C., Ran, H., Diskin, B., Wei, W., Jen, J., Geer, M. J., Araki, K., Ozerdem, U., Simeone, D. M., Miller, G., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0444 · Cited by 315 · see citing works

Active Ras induces heterodimerization of cRaf and BRaf.

Weber, C., Slupsky, J. R., Kalmes, H. A., & Rapp, U. R. (2001) · PubMed · Cited by 312 · see citing works

Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E–mutated melanomas

Smalley, K. S. M., Lioni, M., Palma, M. D., Xiao, M., Desai, B. M., Egyházi, S., Hansson, J., Wu, H., King, A. J., Belle, P. A. V., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0431 · Cited by 310 · see citing works

Targeting ERK1/2 protein-serine/threonine kinases in human cancers

Roskoski, R. J. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.01.039 · Cited by 309 · see citing works

Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3

Sun, C., Hobor, S., Bertotti, A., Zecchin, D., Huang, S., Galimi, F., Cottino, F., Prahallad, A., Grernrum, W., Tzani, A., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.02.045 · Cited by 304 · see citing works

Allosteric Activation of Functionally Asymmetric RAF Kinase Dimers

Hu, J., Stites, E. C., Yu, H., Germino, E., Meharena, H. S., Stork, P. A., Kornev, A. P., Taylor, S. S., & Shaw, A. S. (2013) · Cell · doi:10.1016/j.cell.2013.07.046 · Cited by 303 · see citing works

Combination of vemurafenib and cobimetinib in patients with advanced BRAFV600-mutated melanoma: a phase 1b study

Ribas, A., Gonzalez, R. C., Pavlick, A. C., Hamid, O., Gajewski, T. F., DAUD, A. I., Flaherty, L. E., Logan, T. F., Chmielowski, B., Lewis, K. D., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70301-8 · Cited by 300 · see citing works

Dusp6 (Mkp3) is a negative feedback regulator of FGF-stimulated ERK signaling during mouse development

Li, C., Scott, D., Hatch, E., Tian, X.-Y., & Mansour, S. (2007) · Development · doi:10.1242/dev.02701 · Cited by 298 · see citing works

MEK inhibitors for the treatment of non-small cell lung cancer

Han, J., Liu, Y., Yang, S., Wu, X., Li, H., & Wang, Q. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-01025-7 · Cited by 291 · see citing works

Over-expression of the mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma: Its role in tumor progression and apoptosis

Huynh, H. T., Nguyen, T. T. T., Chow, P. K. H., Tan, P. H., Soo, K. C., & Tran, E. (2003) · BMC Gastroenterology · doi:10.1186/1471-230x-3-19 · Cited by 289 · see citing works

Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma

Kakadia, S., Yarlagadda, N., Awad, R., Kundranda, M., Niu, J., Naraev, B., Mina, L., Dragovich, T., Gimbel, M., & Mahmoud, F. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s182721 · Cited by 277 · see citing works

Inhibition of autophagy potentiates the antitumor effect of the multikinase inhibitor sorafenib in hepatocellular carcinoma

Shimizu, S., Takehara, T., Hikita, H., Kodama, T., Tsunematsu, H., Miyagi, T., Hosui, A., Ishida, H., Tatsumi, T., Kanto, T., et al. (2011) · International Journal of Cancer · doi:10.1002/ijc.26374 · Cited by 266 · see citing works

Mutant BRAF Melanomas—Dependence and Resistance

Poulikakos, P. I., & Rosen, N. X. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.01.008 · Cited by 248 · see citing works

Impact of Feedback Phosphorylation and Raf Heterodimerization on Normal and Mutant B-Raf Signaling

Ritt, D. A., Monson, D. M., Specht, S. I., & Morrison, D. K. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.00569-09 · Cited by 239 · see citing works

Interplay between MAPK/ERK signaling pathway and MicroRNAs: A crucial mechanism regulating cancer cell metabolism and tumor progression

Asl, E. R., Amini, M. A., Najafi, S., Mansoori, B., Mokhtarzadeh, A., Mohammadi, A., Lotfinejad, P., Bagheri, M., Shirjang, S., Lotfi, Z., et al. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119499 · Cited by 232 · see citing works

Nuclear ERK: Mechanism of Translocation, Substrates, and Role in Cancer

Maik-Rachline, G., Hacohen-Lev-Ran, A., & Seger, R. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20051194 · Cited by 225 · see citing works

Effects of Raf Dimerization and Its Inhibition on Normal and Disease-Associated Raf Signaling

Freeman, A. K., Ritt, D. A., & Morrison, D. K. (2013) · Molecular Cell · doi:10.1016/j.molcel.2012.12.018 · Cited by 201 · see citing works

Targeting oncogenic Raf protein-serine/threonine kinases in human cancers

Roskoski, R. J. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.08.013 · Cited by 194 · see citing works

BRAF Inhibitors: Molecular Targeting and Immunomodulatory Actions

Proietti, I., Skroza, N., Michelini, S., Mambrin, A., Balduzzi, V., Bernardini, N., Marchesiello, A., Tolino, E., Volpe, S., Maddalena, P., et al. (2020) · Cancers · doi:10.3390/cancers12071823 · Cited by 192 · see citing works

MEK inhibition reprograms CD8+ T lymphocytes into memory stem cells with potent antitumor effects

Verma, V., Jafarzadeh, N., Boi, S. K., Kundu, S., Jiang, Z., Fan, Y., Lopez, J., Nandre, R. M., Zeng, P., Alolaqi, F., et al. (2020) · Nature Immunology · doi:10.1038/s41590-020-00818-9 · Cited by 183 · see citing works

Identification of the Mitogen-Activated Protein Kinase Phosphorylation Sites on Human Sosl That Regulate Interaction with Grb2

Corbalán‐García, S., Yang, S., Degenhardt, K., & Bar‐Sagi, D. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.10.5674 · Cited by 181 · see citing works

Development of encorafenib for BRAF-mutated advanced melanoma

Koelblinger, P., Olaf, T., & Dummer, R. (2017) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000426 · Cited by 180 · see citing works

RAS-mediated oncogenic signaling pathways in human malignancies

Khan, A. Q., Kuttikrishnan, S., Siveen, K. S., Prabhu, K. S., Shanmugakonar, M., Al‐Naemi, H. A., Haris, M., Dermime, S., & Shahab Uddin, M. S. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.03.001 · Cited by 179 · see citing works

Inhibitors that stabilize a closed RAF kinase domain conformation induce dimerization

Lavoie, H., Thevakumaran, N., Gavory, G., Li, J. J., Padeganeh, A., Guiral, S., Duchaine, J., Mao, D. Y. L., Bouvier, M., Sicheri, F., et al. (2013) · Nature Chemical Biology · doi:10.1038/nchembio.1257 · Cited by 176 · see citing works

Expression of Endogenous Oncogenic V600EB-raf Induces Proliferation and Developmental Defects in Mice and Transformation of Primary Fibroblasts

Mercer, K., Giblett, S. M., Green, S. A., Lloyd, D. J., Dias, S. D. R., Plumb, M., Marais, R., & Pritchard, C. A. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2211 · Cited by 175 · see citing works

Autophagy inhibition overcomes multiple mechanisms of resistance to BRAF inhibition in brain tumors

Mulcahy Levy, J. M., Zahedi, S., Griesinger, A. M., Morin, A., Davies, K. D., Aisner, D. L., Kleinschmidt-DeMasters, B., Fitzwalter, B. E., Goodall, M. L., Thorburn, J., et al. (2017) · eLife · doi:10.7554/elife.19671 · Cited by 175 · see citing works

WNT5A enhances resistance of melanoma cells to targeted BRAF inhibitors

Anastas, J. N., Kulikauskas, R. M., Tamir, T. Y., Rizos, H., Long, G. V., von Euw, E. M., Yang, P., Chen, H., Haydu, L. E., Toroni, R. A., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci70156 · Cited by 174 · see citing works

Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors.

Hellmann, M. D., Kim, T.-W., Lee, C. B., Goh, B.-C., Miller, W. H., Oh, D.-Y., Jamal, R., Chee, C.-E., Chow, L. Q. M., Gainor, J. F., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz113 · Cited by 174 · see citing works

Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways

McCubrey, J. A., Steelman, L. S., Kempf, C., Chappell, W. H., Abrams, S. L., Stivala, F., Malaponte, G., Nicoletti, F., Libra, M., Bäsecke, J., et al. (2011) · Journal of Cellular Physiology · doi:10.1002/jcp.22647 · Cited by 173 · see citing works

PLX4032, a potent inhibitor of the B‐Raf V600E oncogene, selectively inhibits V600E‐positive melanomas

Lee, J. T., Li, L., Brafford, P. A., van den Eijnden, M., Halloran, M. B., Sproesser, K., Haass, N. K., Smalley, K. S. M., Tsai, J. Y., Bollag, G. E., et al. (2010) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2010.00763.x · Cited by 165 · see citing works

Discovery of (S)-1-(1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)pyridin-2(1H)-one (GDC-0994), an Extracellular Signal-Regulated Kinase 1/2 (ERK1/2) Inhibitor in Early Clinical Development

Blake, J. F., Burkard, M., Chan, J., Chen, H., Chou, K.-J., Diaz, D., Dudley, D. A., Gaudino, J. J., Gould, S. E., Grina, J. A., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00389 · Cited by 159 · see citing works

First-in-Human Clinical Trial of Oral ONC201 in Patients with Refractory Solid Tumors

Stein, M. N., Bertino, J. R., Kaufman, H. L., Mayer, T. M., Moss, R. A., Silk, A. W., Chan, N., Malhotra, J. D., Rodriguez, L., Aisner, J., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2658 · Cited by 159 · see citing works

Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma

Deken, M. A., Gadiot, J., Jordanova, E. S., Lacroix, R., van Gool, M. M. J., Kroon, P., Pineda, C., Foppen, M. H. G., Scolyer, R. A., Song, J., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1238557 · Cited by 153 · see citing works

MEK drives BRAF activation through allosteric control of KSR proteins

Lavoie, H., Sahmi, M., Maisonneuve, P., Marullo, S. A., Thevakumaran, N., Jin, T., Kurinov, I. V., Sicheri, F., & Therrien, M. (2018) · Nature · doi:10.1038/nature25478 · Cited by 153 · see citing works

Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors

Moschos, S. J., Sullivan, R. J., Hwu, W., Ramanathan, R. K., Adjei, A. A., Fong, P. C. C., Shapira‐Frommer, R., Tawbi, H. A.-H., Rubino, J., Rush, T. S., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.92352 · Cited by 151 · see citing works

Targeted Therapy in Advanced Thyroid Cancer to Resensitize Tumors to Radioactive Iodine

Jaber, T., Waguespack, S. G., Cabanillas, M. E., Elbanan, M., Vu, T. H., Dadu, R., Sherman, S. I., Amit, M., Santos, E. B., Zafereo, M., et al. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00612 · Cited by 142 · see citing works

Ras activation revisited: role of GEF and GAP systems

Hennig, A., Markwart, R., Esparza-Franco, M. A., Ladds, G., & Rubio, I. (2015) · Biological Chemistry · doi:10.1515/hsz-2014-0257 · Cited by 141 · see citing works

Encorafenib and Binimetinib: First Global Approvals

Shirley, M. (2018) · Drugs · doi:10.1007/s40265-018-0963-x · Cited by 141 · see citing works

Phase II Trial of MEK Inhibitor Selumetinib (AZD6244, ARRY-142886) in Patients with BRAFV600E/K-Mutated Melanoma

Catalanotti, F., Solit, D. B., Pulitzer, M. P., Berger, M. F., Scott, S. N., Iyriboz, T. A., Lacouture, M. E., Panageas, K. S., Wolchok, J. D., Carvajal, R. D., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3476 · Cited by 134 · see citing works

Radiosensitization by BRAF inhibitor therapy—mechanism and frequency of toxicity in melanoma patients

Hecht, M., Zimmer, L., Loquai, C., Weishaupt, C., Gutzmer, R., Schuster, B., Gleisner, S., Schulze, B., Goldinger, S. M., Berking, C., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv139 · Cited by 132 · see citing works

ERK-Dependent MKP-1–Mediated Cisplatin Resistance in Human Ovarian Cancer Cells

Wang, J., Zhou, J., & Wu, G. S. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-5185 · Cited by 129 · see citing works

Identification of novel ERK-mediated feedback phosphorylation sites at the C-terminus of B-Raf

Brummer, T., Naegele, H., Reth, M. G., & Misawa, Y. (2003) · Oncogene · doi:10.1038/sj.onc.1207185 · Cited by 115 · see citing works

Selumetinib: First Approval

Markham, A., & Keam, S. J. (2020) · Drugs · doi:10.1007/s40265-020-01331-x · Cited by 112 · see citing works

Mapping the molecular determinants of BRAF oncogene dependence in human lung cancer

Lin, L., Asthana, S., Chan, E., Bandyopadhyay, S., Martins, M. M., Olivas, V. R., Yan, J. J., Pham, L. Q., Wang, M. M., Bollag, G. E., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1320956111 · Cited by 104 · see citing works

Increased MAPK Activity and MKP-1 Overexpression in Human Gastric Adenocarcinoma

Bang, Y., Kwon, J. H., Kang, S. H., Kim, J. W., & Yang, Y. C. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.9256 · Cited by 104 · see citing works

Grb2, a Double-Edged Sword of Receptor Tyrosine Kinase Signaling

Belov, A. A., & Mohammadi, M. (2012) · Science Signaling · doi:10.1126/scisignal.2003576 · Cited by 103 · see citing works

Oncogenic PI3K/AKT promotes the step-wise evolution of combination BRAF/MEK inhibitor resistance in melanoma

Irvine, M., Stewart, A., Pedersen, B., Boyd, S., Kefford, R., & Rizos, H. (2018) · Oncogenesis · doi:10.1038/s41389-018-0081-3 · Cited by 100 · see citing works

PD-L1 Expression and Immune Escape in Melanoma Resistance to MAPK Inhibitors

Kakavand, H., Rawson, R. V., Pupo, G. M., Yang, J. Y. H., Menzies, A. M., Carlino, M. S., Kefford, R. F., Howle, J. R., Saw, R. P. M., Thompson, J. F., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1688 · Cited by 92 · see citing works

Immunotherapy Combined or Sequenced With Targeted Therapy in the Treatment of Solid Tumors: Current Perspectives

Atkins, M. B., & Larkin, J. (2016) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv414 · Cited by 91 · see citing works

Integrin α6/Akt/Erk signaling is essential for human breast cancer resistance to radiotherapy

Hu, T., Zhou, R., Zhao, Y., & Wu, G. (2016) · Scientific Reports · doi:10.1038/srep33376 · Cited by 91 · see citing works

A First-in-Human Phase I Study to Evaluate the ERK1/2 Inhibitor GDC-0994 in Patients with Advanced Solid Tumors

Varga, A., Soria, J., Hollebecque, A., LoRusso, P. M., Bendell, J. C., Huang, S.-M. A., Wagle, M.-C., Okrah, K., Liu, L., Murray, E. R., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2574 · Cited by 89 · see citing works

RSK phosphorylates SOS1 creating 14-3-3-docking sites and negatively regulating MAPK activation

Saha, M., Carriere, A., Cheerathodi, M., Zhang, X., Lavoie, G., Rush, A. J., Roux, P. P., & Ballif, B. A. (2012) · Biochemical Journal · doi:10.1042/bj20120938 · Cited by 88 · see citing works

PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma

Ribas, A., Algazi, A. P., Ascierto, P. A., Butler, M. O., Chandra, S., Gordon, M. S., Hernandez-Aya, L. F., Lawrence, D. P., Lutzky, J., Miller, W. H., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19810-w · Cited by 88 · see citing works

Loss of cohesin complex components STAG2 or STAG3 confers resistance to BRAF inhibition in melanoma

Shen, C., Kim, S. H., Trousil, S., Frederick, D. T., Piris, A., Yuan, P., Cai, L., Gu, L., Li, M., Lee, J. H., et al. (2016) · Nature Medicine · doi:10.1038/nm.4155 · Cited by 86 · see citing works

Targeting Mitochondrial Metabolism by Inhibiting Autophagy in BRAF-Driven Cancers

Strohecker, A. M., & White, E. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0196 · Cited by 83 · see citing works

A Landscape of Therapeutic Cooperativity in KRAS Mutant Cancers Reveals Principles for Controlling Tumor Evolution

Anderson, G. R., Winter, P. S., Lin, K. H., Nussbaum, D. P., Cakir, M., Stein, E. M., Soderquist, R. S., Crawford, L., Leeds, J. C., Newcomb, R., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.07.006 · Cited by 80 · see citing works

Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges

Tang, D., Kroemer, G., & Kang, R. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01422-7 · Cited by 80 · see citing works

MEK inhibition may increase survival of NRAS-mutated melanoma patients treated with checkpoint blockade: Results of a retrospective multicentre analysis of 364 patients

Kirchberger, M. C., Ugurel, S., Mangana, J., Heppt, M. V., Eigentler, T., Berking, C., Schadendorf, D., Schuler, G., Dummer, R., & Heinzerling, L. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.04.010 · Cited by 78 · see citing works

Identification of the MEK1(F129L) Activating Mutation as a Potential Mechanism of Acquired Resistance to MEK Inhibition in Human Cancers Carrying the B-Raf V600E Mutation

Wang, H., Daouti, S., Li, W., Yang, W., Rizzo, C., Higgins, B., Packman, K. E., Rosen, N. X., Boylan, J. F., Heimbrook, D. C., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-4351 · Cited by 76 · see citing works

The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment

Poon, E., Mullins, S., Watkins, A., Williams, G. S., Koopmann, J., Genova, G. D., Cumberbatch, M., Veldman-Jones, M. H., Grosskurth, S. E., Sah, V. R., et al. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0268-8 · Cited by 75 · see citing works

Overcoming Resistance to Dual Innate Immune and MEK Inhibition Downstream of KRAS

Kitajima, S., Asahina, H., Chen, T., Guo, S., Quiceno, L. G., Cavanaugh, J. D., Merlino, A. A., Tange, S., Terai, H., Kim, J. W., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.08.009 · Cited by 75 · see citing works

Serious Skin Toxicity With the Combination of BRAF Inhibitors and Radiotherapy

Satzger, I., Degen, A., Asper, H., Kapp, A., Hauschild, A., & Gutzmer, R. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.4265 · Cited by 74 · see citing works

Pulsatile MEK inhibition improves anti-tumor immunity and T cell function in murine Kras mutant lung cancer

Choi, H., Deng, J., Li, S., Silk, T., Dong, L., Brea, E. J., Houghton, S., Redmond, D., Zhong, H., Boiarsky, J., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.03.066 · Cited by 72 · see citing works

Targeting Autophagy Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib

Wang, W., Kang, H. H., Zhao, Y., Min, I. M., Wyrwas, B., Moore, M. D., Teng, L., Zarnegar, R., Jiang, X., & Fahey, T. J. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-1999 · Cited by 71 · see citing works

Biological Rationale for Targeting MEK/ERK Pathways in Anti-Cancer Therapy and to Potentiate Tumour Responses to Radiation

Marampon, F., Ciccarelli, C., & ZANI, B. M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20102530 · Cited by 66 · see citing works

Immune checkpoint blockade and its combination therapy with small-molecule inhibitors for cancer treatment

Wang, M., Liu, Y., Cheng, Y., Wei, Y., & Wei, X. (2019) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.12.002 · Cited by 66 · see citing works

PTEN Loss-of-Function Alterations Are Associated With Intrinsic Resistance to BRAF Inhibitors in Metastatic Melanoma

Catalanotti, F., Cheng, D. T., Shoushtari, A. N., Johnson, D. B., Panageas, K. S., Momtaz, P., Higham, C., Won, H. H., Harding, J. J., Merghoub, T., et al. (2017) · JCO Precision Oncology · doi:10.1200/po.16.00054 · Cited by 63 · see citing works

Identification of Major ERK-Related Phosphorylation Sites in Gab1

Lehr, S., Kotzka, J., Avci, H., Sickmann, A., Meyer, H. E., Herkner, A., & Müller‐Wieland, D. (2004) · Biochemistry · doi:10.1021/bi049753e · Cited by 61 · see citing works

Inhibiting BRAF Oncogene–Mediated Radioresistance Effectively Radiosensitizes BRAFV600E-Mutant Thyroid Cancer Cells by Constraining DNA Double-Strand Break Repair

Robb, R. N., Yang, L., Shen, C., Wolfe, A. R., Webb, A., Zhang, X., Vedaie, M., Saji, M., Jhiang, S. M., Ringel, M. D., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3625 · Cited by 60 · see citing works

Clinical responses to ERK inhibition in BRAF V600E-mutant colorectal cancer predicted using a computational model

Kirouac, D. C., Schaefer, G., Chan, J., Merchant, M., Orr, C., Huang, S.-M. A., Moffat, J., Liu, L., Gadkar, K., & Ramanujan, S. (2017) · npj Systems Biology and Applications · doi:10.1038/s41540-017-0016-1 · Cited by 60 · see citing works

Ulixertinib (BVD-523) antagonizes ABCB1- and ABCG2-mediated chemotherapeutic drug resistance

Ji, N., Yang, Y., Lei, Z., Cai, C., Wang, J., Gupta, P., Xian, X., Yang, D., Kong, D., & Chen, Z. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.10.028 · Cited by 60 · see citing works

SHOC2 and CRAF Mediate ERK1/2 Reactivation in Mutant NRAS-mediated Resistance to RAF Inhibitor

Kaplan, F. M., Kugel, C. H., Dadpey, N., Shao, Y., Abel, E. V., & Aplin, A. E. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.390906 · Cited by 59 · see citing works

Role of protein phosphatases in the cancer microenvironment

Ruvolo, P. P. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2018.07.006 · Cited by 59 · see citing works

Activating mutations in MEK1 enhance homodimerization and promote tumorigenesis

Yuan, J., Ng, W. H., Tian, Z., Yap, J., Baccarini, M., Chen, Z., & Hu, J. (2018) · Science Signaling · doi:10.1126/scisignal.aar6795 · Cited by 59 · see citing works

A Phase Ib Study to Evaluate the MEK Inhibitor Cobimetinib in Combination with the ERK1/2 Inhibitor GDC-0994 in Patients with Advanced Solid Tumors

Weekes, C. D., Lockhart, A. C., LoRusso, P. M., Murray, E. R., Park, E., Tagen, M., Singh, J., Sarkar, I., Müeller, L., Dokainish, H., et al. (2020) · The Oncologist · doi:10.1634/theoncologist.2020-0292 · Cited by 58 · see citing works

The dimer-dependent catalytic activity of RAF family kinases is revealed through characterizing their oncogenic mutants

Yuan, J., Ng, W. H., Lam, P. Y. P., Wang, Y., Xia, H., Yap, J., Guan, S. P., Lee, A. S. G., Wang, M., Baccarini, M., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0365-2 · Cited by 55 · see citing works

Dynamic Modeling and Analysis of the Cross-Talk between Insulin/AKT and MAPK/ERK Signaling Pathways

Arkun, Y. (2016) · PLoS ONE · doi:10.1371/journal.pone.0149684 · Cited by 54 · see citing works

Concurrent MEK and autophagy inhibition is required to restore cell death associated danger-signalling in Vemurafenib-resistant melanoma cells

Martin, S., Dudek-Perić, A. M., Maes, H., Garg, A. D., Gabrysiak, M., Demirsoy, S., Swinnen, J. V., & Agostinis, P. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.12.003 · Cited by 54 · see citing works

MK-8353: Discovery of an Orally Bioavailable Dual Mechanism ERK Inhibitor for Oncology

Boga, S. B., Deng, Y., Zhu, L. W., Yang, N., Cooper, A. B., Shipps, G. W., Doll, R. J., Shih, N., Zhu, H. Y. H., Sun, R., et al. (2018) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.8b00220 · Cited by 53 · see citing works

BRAF Splice Variant Resistance to RAF Inhibitor Requires Enhanced MEK Association

Vido, M. J., Le, K., Hartsough, E. J., & Aplin, A. E. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.10.049 · Cited by 52 · see citing works

FDA Approves First KRAS Inhibitor: Sotorasib

(2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-nb2021-0362 · Cited by 52 · see citing works

Sorafenib does not improve efficacy of chemotherapy in advanced pancreatic cancer: A GISCAD randomized phase II study

Cascinu, S., Berardi, R., Sobrero, A. F., Bidoli, P., Labianca, R., Siena, S., Ferrari, D., Barni, S., Aitini, E., Zagonel, V., et al. (2013) · Digestive and Liver Disease · doi:10.1016/j.dld.2013.09.020 · Cited by 51 · see citing works

MEK Inhibition Overcomes Cisplatin Resistance Conferred by SOS/MAPK Pathway Activation in Squamous Cell Carcinoma

Kong, L. R., Chua, K. N., Sim, W. J., Ng, H. C., Bi, C., Ho, J., Nga, M. E., Pang, Y. H., Ong, W. R., Soo, R. A., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0062 · Cited by 50 · see citing works

ERK Regulates HIF1α-Mediated Platinum Resistance by Directly Targeting PHD2 in Ovarian Cancer

Li, Z., Zhou, W., Zhang, Y., Sun, W., Yung, M. M. H., Sun, J. F., Li, J., Chen, C., Li, Z., Meng, Y., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-4145 · Cited by 50 · see citing works

BRAF mutation and its inhibitors in sarcoma treatment

Liu, H., Nahar, N., Hassan, S., Liu, X., & Yang, J. (2020) · Cancer Medicine · doi:10.1002/cam4.3103 · Cited by 49 · see citing works

Kinase-independent role for CRAF-driving tumour radioresistance via CHK2

Advani, S. J., Camargo, M. F., Seguin, L., Mielgo, A., Anand, S., Hicks, A. M., Aguilera, J. A., Franovic, A., Weis, S. M., & Cheresh, D. A. (2015) · Nature Communications · doi:10.1038/ncomms9154 · Cited by 47 · see citing works

Astaxanthin increases radiosensitivity in esophageal squamous cell carcinoma through inducing apoptosis and G2/M arrest

Qian, X., Tan, C., Yang, B., Wang, F., Ge, Y., Guan, Z., & Cai, J. (2017) · Diseases of the Esophagus · doi:10.1093/dote/dox027 · Cited by 47 · see citing works

Safety and efficacy of the BRAF inhibitor dabrafenib in relapsed or refractory hairy cell leukemia: a pilot phase-2 clinical trial

Tiacci, E., Carolis, L. D., Simonetti, E., Merluzzi, M., Bennati, A., Perriello, V. M., Pucciarini, A., Santi, A., Venanzi, A., Pettirossi, V., et al. (2021) · Leukemia · doi:10.1038/s41375-021-01210-8 · Cited by 47 · see citing works

Inhibition of the CRAF/prohibitin interaction reverses CRAF-dependent resistance to vemurafenib

Doudican, N. A., & Orlow, S. J. (2016) · Oncogene · doi:10.1038/onc.2016.214 · Cited by 42 · see citing works

Impressive response to dabrafenib, trametinib, and osimertinib in a metastatic EGFR-mutant/BRAF V600E lung adenocarcinoma patient

Ribeiro, M. F. S. A., Knebel, F. H., Bettoni, F., Saddi, R., Sacardo, K. P., Canedo, F. S. N. A., Alessi, J. V. M., Shimada, A. K., Marin, J. F. G., Camargo, A. A., et al. (2021) · npj Precision Oncology · doi:10.1038/s41698-021-00149-4 · Cited by 42 · see citing works

BRAFV600E inhibition stimulates AMP-activated protein kinase-mediated autophagy in colorectal cancer cells

Sueda, T., Sakai, D., Kawamoto, K., Konno, M., Nishida, N., Koseki, J., Colvin, H. S., Takahashi, H., Haraguchi, N., Nishimura, J., et al. (2016) · Scientific Reports · doi:10.1038/srep18949 · Cited by 41 · see citing works

Survival advantage combining a BRAF inhibitor and radiation in BRAF V600E-mutant glioma

Dasgupta, T., Olow, A., Yang, X., Hashizume, R., Nicolaides, T. P., Tom, M. W., Aoki, Y., Berger, M. S., Weiss, W. A., Stalpers, L. J. A., et al. (2015) · Journal of Neuro-Oncology · doi:10.1007/s11060-015-1939-2 · Cited by 41 · see citing works

MEK inhibitors for the treatment of NRAS mutant melanoma

Sarkisian, S., & Davar, D. (2018) · Drug Design, Development and Therapy · doi:10.2147/dddt.s131721 · Cited by 40 · see citing works

Concurrent HER or PI3K Inhibition Potentiates the Antitumor Effect of the ERK Inhibitor Ulixertinib in Preclinical Pancreatic Cancer Models

Jiang, H., Xu, M., Li, L., Grierson, P. M., Dodhiawala, P. B., Highkin, M. K., Zhang, D., Li, Q., Wang‐Gillam, A., & Lim, K. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-1142 · Cited by 40 · see citing works

Structural snapshots of RAF kinase interactions

Adariani, S. R., Buchholzer, M., Akbarzadeh, M., Nakhaei‐Rad, S., Dvorský, R., & Ahmadian, M. R. (2018) · Biochemical Society Transactions · doi:10.1042/bst20170528 · Cited by 40 · see citing works

Loss of BOP1 confers resistance to BRAF kinase inhibitors in melanoma by activating MAP kinase pathway

Gupta, R., Bugide, S., Wang, B., Green, M. R., Johnson, D. B., & Wajapeyee, N. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1821889116 · Cited by 40 · see citing works

Extracellular Signal-Regulated Kinase (ERK) Inhibitors in Oncology Clinical Trials

Chin, H. M., Lai, D. K., & Falchook, G. S. (2019) · Journal of Immunotherapy and Precision Oncology · doi:10.4103/jipo.jipo_17_18 · Cited by 40 · see citing works

LY3214996 relieves acquired resistance to sorafenib in hepatocellular carcinoma cells

Ma, Y., Xu, R., Liu, X., Zhang, Y., Li, S., Qiu, X., Cai, S., Zhou, S., Xie, Y., Li, A., et al. (2021) · International Journal of Medical Sciences · doi:10.7150/ijms.51256 · Cited by 40 · see citing works

Clinical outcome of concomitant vs interrupted BRAF inhibitor therapy during radiotherapy in melanoma patients

Hecht, M., Meier, F. E., Zimmer, L., Polat, B., Loquai, C., Weishaupt, C., Forschner, A., Gutzmer, R., Utikal, J. S., Goldinger, S. M., et al. (2018) · British Journal of Cancer · doi:10.1038/bjc.2017.489 · Cited by 39 · see citing works

Advances in the systemic treatment of melanoma brain metastases

Oliva, I. C. G., Schvartsman, G., & Tawbi, H. A. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy185 · Cited by 39 · see citing works

Novel induction of CD40 expression by tumor cells with RAS/RAF/PI3K pathway inhibition augments response to checkpoint blockade

Yan, C. W., Saleh, N., Yang, J., Nebhan, C. A., Vilgelm, A. E., Reddy, E. P., Roland, J. T., Johnson, D. B., Chen, S., Shattuck-Brandt, R. L., et al. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01366-y · Cited by 39 · see citing works

The Biology and Clinical Development of MEK Inhibitors for Cancer

Luke, J., Ott, P., & Shapiro, G. (2014) · Drugs · doi:10.1007/s40265-014-0315-4 · Cited by 38 · see citing works

ERK Inhibitor LY3214996-Based Treatment Strategies forRAS-Driven Lung Cancer

Köhler, J., Zhao, Y., Li, J., Gokhale, P. C., Tiv, H. L., Knott, A., Wilkens, M. K., Soroko, K. M., Lin, M., Ambrogio, C., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0531 · Cited by 36 · see citing works

The adjuvant treatment revolution for high-risk melanoma patients

Spagnolo, F., Boutros, A., Tanda, E. T., & Queirolo, P. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.08.024 · Cited by 35 · see citing works

Combination of BRAF Inhibitors and Brain Radiotherapy in Patients With Metastatic Melanoma Shows Minimal Acute Toxicity

Rompoti, N., Schilling, B., Livingstone, E., Griewank, K., Hillen, U., Sauerwein, W. A. G., Pöttgen, C., Stuschke, M., Schadendorf, D., & Zimmer, L. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.8473 · Cited by 33 · see citing works

Distinct genomic landscapes of gastroesophageal adenocarcinoma depending on PD-L1 expression identify mutations in RAS–MAPK pathway and TP53 as potential predictors of immunotherapy efficacy

Wang, J., Xiu, J., Baca, Y., Arai, H., Battaglin, F., Kawanishi, N. K., Soni, S., Zhang, W., Millstein, J., Shields, A. F., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.03.203 · Cited by 27 · see citing works

Current developments in extracellular-regulated protein kinase (ERK1/2) inhibitors

Niu, Y., & Ji, H. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.01.012 · Cited by 27 · see citing works

Phase I dose-finding study of oral ERK1/2 inhibitor LTT462 in patients (pts) with advanced solid tumors harboring MAPK pathway alterations.

Jankú, F., Élez, E., Iyer, G., Yamamoto, N., Tan, D. S.-W., Stathis, A., Stammberger, U. M., Evans, H., Seroutou, A., Mais, A., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.15_suppl.3640 · Cited by 26 · see citing works

BRAF V600E-dependent role of autophagy in uveal melanoma

Zhao, Y., Wang, W., Min, I., Wyrwas, B., Moore, M., Zarnegar, R., & Fahey, T. J. (2017) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-016-2317-y · Cited by 26 · see citing works

The Benefit of Reactivating p53 under MAPK Inhibition on the Efficacy of Radiotherapy in Melanoma

Krayem, M., Sabbah, M., Najem, A., Wouters, A., Lardon, F., Simon, S., Salès, F., Journe, F., Awada, A. H., Ghanem, G., et al. (2019) · Cancers · doi:10.3390/cancers11081093 · Cited by 25 · see citing works

Transcriptional Activation of Gstp1 by MEK/ERK Signaling Confers Chemo-Resistance to Cisplatin in Lung Cancer Stem Cells

Li, J., Ye, T., Liu, Y., Kong, L., Sun, Z., Liu, D., Wang, J., & Xing, H. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00476 · Cited by 24 · see citing works

Autophagy-Dependent Survival of Mutant B-Raf Melanoma Cells Selected for Resistance to Apoptosis Induced by Inhibitors against Oncogenic B-Raf

Ahn, J.-H., & Lee, M. (2013) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2013.012 · Cited by 23 · see citing works

A matching-adjusted indirect comparison of combination nivolumab plus ipilimumab with BRAF plus MEK inhibitors for the treatment of BRAF-mutant advanced melanoma☆

Tarhini, A. A., Toor, K. K., Chan, K., McDermott, D. F., Mohr, P., Larkin, J., Hodi, F. S., Lee, C.-H., Rizzo, J. I., Johnson, H., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100050 · Cited by 23 · see citing works

Regulation of ERK Kinase by MEK1 Kinase Inhibition in the Brain

Tassin, T. C., Benavides, D. R., Plattner, F., Nishi, A., & Bibb, J. A. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.654897 · Cited by 22 · see citing works

Activated ERK Signaling Is One of the Major Hub Signals Related to the Acquisition of Radiotherapy-Resistant MDA-MB-231 Breast Cancer Cells

Paramanantham, A., Jung, E. J., Go, S., Jeong, B. K., Jung, J., Hong, S., Kim, G. S., & Lee, W. S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094940 · Cited by 22 · see citing works

Inhibition of BRAF and ERK1/2 has synergistic effects on thyroid cancer growth in vitro and in vivo

Hicks, H. M., McKenna, L. R., Espinoza, V. L., Pozdeyev, N. V., Pike, L. A., Sams, S. B., LaBarbera, D. V., Reigan, P., Raeburn, C. D., & Schweppe, R. E. (2021) · Molecular Carcinogenesis · doi:10.1002/mc.23284 · Cited by 21 · see citing works

Sorafénib et radiothérapie dans le carcinome hépatocellulaire

Girard, N., & Mornex, F. (2011) · Cancer/Radiothérapie · doi:10.1016/j.canrad.2010.11.012 · Cited by 19 · see citing works

A Phase 2 Clinical Trial of Trametinib and Low-Dose Dabrafenib in Patients with Advanced Pretreated NRASQ61R/K/L Mutant Melanoma (TraMel-WT)

Awada, G., Schwarze, J. K., Tijtgat, J., Fasolino, G., Everaert, H., & Neyns, B. (2021) · Cancers · doi:10.3390/cancers13092010 · Cited by 19 · see citing works

Oncogenic BRAF inhibitor UAI-201 induces cell cycle arrest and autophagy in BRAF mutant glioma cells

Ahn, J., Lee, Y. W., Ahn, S. K., & Lee, M. (2014) · Life Sciences · doi:10.1016/j.lfs.2014.03.026 · Cited by 18 · see citing works

Rational design, synthesis, and biological evaluation of Pan-Raf inhibitors to overcome resistance

Wang, L., Zhu, G., Zhang, Q., Duan, C., Zhang, Y., Zhang, Z., Zhou, Y., Lu, T., & Tang, W. (2017) · Organic & Biomolecular Chemistry · doi:10.1039/c7ob00518k · Cited by 18 · see citing works

TIC10/ONC201: a bend in the road to clinical development

Greer, Y. E., & Lipkowitz, S. (2015) · Oncoscience · doi:10.18632/oncoscience.133 · Cited by 18 · see citing works

Phase I/II Trial of Immunotherapy With Durvalumab and Tremelimumab With Continuous or Intermittent MEK Inhibitor Selumetinib in NSCLC: Early Trial Report

Gaudreau, P.-O., Lee, J. J., Heymach, J. V., & Gibbons, D. L. (2020) · Clinical Lung Cancer · doi:10.1016/j.cllc.2020.02.019 · Cited by 17 · see citing works

Cobimetinib (GDC-0973, XL518)

Andrlová, H., Zeiser, R., & Meiß, F. (2018) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-319-91442-8_12 · Cited by 16 · see citing works

Vemurafenib Plus Cobimetinib in the Treatment of Mutated Metastatic Melanoma: The CoBRIM Trial

Grimaldi, A. M., Simeone, E., & Ascierto, P. A. (2015) · Melanoma Management · doi:10.2217/mmt.15.22 · Cited by 15 · see citing works

Combination of paclitaxel, bevacizumab and MEK162 in second line treatment in platinum-relapsing patient derived ovarian cancer xenografts

Ricci, F., Guffanti, F., Damia, G. L. M., & Broggini, M. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0662-3 · Cited by 15 · see citing works

A comparative study of the cutaneous side effects between BRAF monotherapy and BRAF/MEK inhibitor combination therapy in patients with advanced melanoma: a single-centre experience

Russo, I., Zorzetto, L., Frigo, A. C., Chiarion‐Sileni, V., & Alaibac, M. (2017) · European Journal of Dermatology · doi:10.1684/ejd.2017.3069 · Cited by 15 · see citing works

The safety and efficacy of cobimetinib for the treatment of BRAF V600E or V600K melanoma

Amaral, T. M. S., Nouri, N., & Garbe, C. (2016) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2016.1192469 · Cited by 13 · see citing works

Canadian Cancer Trials Group (CCTG) IND215: A phase Ib study of Selumetinib in patients with untreated advanced or metastatic NSCLC who are receiving standard chemotherapy regimens

Goffin, J. R., Nicholas, G. A., Mates, M., Tu, D., CHEN, E., Laurie, S. A., Juergens, R. A., Robinson, A. G., Goss, G. D., Reaume, M. N., et al. (2018) · Investigational New Drugs · doi:10.1007/s10637-018-0680-z · Cited by 13 · see citing works

Contemporary Neoadjuvant Therapies for High-Risk Melanoma: A Systematic Review

Boulva, K., Apte, S. S., Yu, A. M., Tran, A., Shorr, R., Song, X., Ong, M., & Nessim, C. (2021) · Cancers · doi:10.3390/cancers13081905 · Cited by 13 · see citing works

Preclinical studies with ONC201/TIC10 and lurbinectedin as a novel combination therapy in small cell lung cancer (SCLC).

Liguori, N. R., Uruchurtu, A. S. S., Zhang, L., Abbas, A. E., Lee, Y. S., Zhou, L., Azzoli, C. G., & El‐Deiry, W. S. (2022) · PubMed Central · Cited by 13 · see citing works

Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer

van Golen, R. F., & Dekker, T. J. A. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30554-4 · Cited by 13 · see citing works

Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies

Bahar, M. E., Kim, H. J., & Kim, D. R. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01705-z · Cited by 888 · see citing works

Navigating the ERK1/2 MAPK Cascade

Martín-Vega, A., & Cobb, M. H. (2023) · Biomolecules · doi:10.3390/biom13101555 · Cited by 124 · see citing works

Oxidative Stress and Cancer Therapy: Controlling Cancer Cells Using Reactive Oxygen Species

Ju, S., Singh, M. K., Han, S., Ranbhise, J. S., Ha, J., Choe, W., Yoon, K., Yeo, S. G., Kim, S. S., & Kang, I. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252212387 · Cited by 129 · see citing works

Roles and inhibitors of FAK in cancer: current advances and future directions

Hu, H.-H., Wang, S., Shang, H.-L., Lv, H., Chen, B., Gao, S., & Chen, X. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1274209 · Cited by 91 · see citing works

Heat shock proteins as hallmarks of cancer: insights from molecular mechanisms to therapeutic strategies

Zuo, W., Pang, Q., Zhu, X., Yang, Q., Zhao, Q., He, G., Han, B., & Huang, W. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01601-1 · Cited by 88 · see citing works

Multiple myeloma: signaling pathways and targeted therapy

Lu, Q., Yang, D., Li, H., Niu, T., & Tong, A. (2024) · Molecular biomedicine · doi:10.1186/s43556-024-00188-w · Cited by 90 · see citing works

New Directions in the Therapy of Glioblastoma

Szklener, K., Mazurek, M., Wieteska, M., Wacławska, M., Bilski, M., & Mańdziuk, S. (2022) · Cancers · doi:10.3390/cancers14215377 · Cited by 84 · see citing works

The current landscape of the antimicrobial peptide melittin and its therapeutic potential

Zhang, H.-Q., Sun, C., Xu, N., & Liu, W. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1326033 · Cited by 73 · see citing works

The impact of ribosome biogenesis in cancer: from proliferation to metastasis

Hwang, S.-P., & Denicourt, C. (2024) · NAR Cancer · doi:10.1093/narcan/zcae017 · Cited by 69 · see citing works

Targeting the MAPK signaling pathway: implications and prospects of flavonoids in 3P medicine as modulators of cancer cell plasticity and therapeutic resistance in breast cancer patients

Kubatka, P., Bojková, B., Nosálová, N., Huniadi, M., Samuel, S. M., Sreenesh, B., Hrkľová, G., Kajo, K., Horňák, S., Cizkova, D., et al. (2025) · The EPMA Journal · doi:10.1007/s13167-025-00407-6 · Cited by 53 · see citing works

The tumor microbiome in cancer progression: mechanisms and therapeutic potential

Zhang, W., Xiang, Y., Ren, H., Liu, Y., Wang, Q., Ran, M., Zhou, W., Lu, T., Zheng, X., Qiao, C., et al. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02403-w · Cited by 55 · see citing works

Bladder cancer biomarkers: current approaches and future directions

Ahangar, M., Mahjoubi, F., & Mowla, S. J. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1453278 · Cited by 48 · see citing works

Overcoming cancer therapy resistance: From drug innovation to therapeutics

Wei, J., Lu, M., Wei, T., Fleishman, J. S., Yu, H. J., Chen, X.-L., Kong, X.-T., Sun, S., Li, N., Yang, Y., et al. (2025) · Drug Resistance Updates · doi:10.1016/j.drup.2025.101229 · Cited by 50 · see citing works

Mechanisms of Melanoma Progression and Treatment Resistance: Role of Cancer Stem-like Cells

Hmada, Y. A., Brodell, R. T., Kharouf, N., Flanagan, T. W., AlAmodi, A. A., Hassan, S.-Y., Shalaby, H., Hassan, S.-L., Haïkel, Y., Megahed, M., et al. (2024) · Cancers · doi:10.3390/cancers16020470 · Cited by 40 · see citing works

In Silico Strategies for Designing of Peptide Inhibitors of Oncogenic K-Ras G12V Mutant: Inhibiting Cancer Growth and Proliferation

Ghufran, M., Khan, H. A., Ullah, M., Ghufran, S., Ayaz, M., Siddiq, M., Hassan, S. S. U., & BUNGAU, S. G. (2022) · Cancers · doi:10.3390/cancers14194884 · Cited by 39 · see citing works

Survival strategies of cancer cells: the role of macropinocytosis in nutrient acquisition, metabolic reprogramming, and therapeutic targeting

Xu, G., Zhang, Q., Cheng, R., Qu, J., & Li, W. (2025) · Autophagy · doi:10.1080/15548627.2025.2452149 · Cited by 38 · see citing works

Biodegradable zinc-based metallic materials: Mechanisms, properties, and applications

Yang, H., Huang, H., Li, S., Qin, Y., Wen, P., Qu, X., Jia, B., & Zheng, Y. (2025) · Progress in Materials Science · doi:10.1016/j.pmatsci.2025.101584 · Cited by 38 · see citing works

Targeting KRAS in Colorectal Cancer: A Bench to Bedside Review

Bteich, F., Mohammadi, M., Li, T., Bhat, M. A., Sofianidi, A. A., Wei, N., & Kuang, C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241512030 · Cited by 32 · see citing works

Additively Manufactured Biodegradable Zn‐Based Porous Scaffolds to Suppress Osteosarcoma and Promote Osteogenesis

Lu, Y., Liu, A., Jin, S., Dai, J., Yu, Y., Wen, P., Zheng, Y., & Xia, D. (2024) · Advanced Materials · doi:10.1002/adma.202410589 · Cited by 32 · see citing works

Natural Chalcones and Derivatives in Colon Cancer: Pre-Clinical Challenges and the Promise of Chalcone-Based Nanoparticles

Hba, S., Ghaddar, S., Wahnou, H., Pinon, A., Kebbaj, R. E., Pouget, C., Sol, V., Liagre, B., Oudghiri, M., & Limami, Y. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15122718 · Cited by 30 · see citing works

It’s all downstream from here: RTK/Raf/MEK/ERK pathway resistance mechanisms in glioblastoma

Yakubov, R., Kaloti, R., Persaud, P., McCracken, A., Zadeh, G. M., & Bunda, S. (2025) · Journal of Neuro-Oncology · doi:10.1007/s11060-024-04930-w · Cited by 28 · see citing works

Drug development advances in human genetics‐based targets

Zhang, X., Yu, W., Li, Y., Wang, A., Cao, H., & Fu, Y. (2024) · MedComm · doi:10.1002/mco2.481 · Cited by 25 · see citing works

Sirtuins as Key Regulators in Pancreatic Cancer: Insights into Signaling Mechanisms and Therapeutic Implications

Chouhan, S., Kumar, A., Muhammad, N., Usmani, D., & Khan, T. H. (2024) · Cancers · doi:10.3390/cancers16234095 · Cited by 30 · see citing works

Therapeutic targeting of p90 ribosomal S6 kinase

Wright, E. B., & Lannigan, D. A. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1297292 · Cited by 23 · see citing works

Natural products modulating MAPK for CRC treatment: a promising strategy

Zhou, L., Zhang, J., Zhao, K., Chen, B., & Sun, Z. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1514486 · Cited by 23 · see citing works

Lactate metabolism reprogramming in PDAC: Potential for tumor therapy

Gao, F., Sun, K., Wang, S., Zhang, X., & Bai, X. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189373 · Cited by 22 · see citing works

Development and In Vitro Evaluation of Crizotinib-Loaded Lipid–Polymer Hybrid Nanoparticles Using Box–Behnken Design in Non-small Cell Lung Cancer

Aktas, P. K., Baysal, İ., Ciftci, S. Y., & Arıca, B. (2023) · AAPS PharmSciTech · doi:10.1208/s12249-023-02634-4 · Cited by 21 · see citing works

Tumor Cell Resistance to the Inhibition of BRAF and MEK1/2

Chen, W., & Park, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914837 · Cited by 20 · see citing works

Mutations in the Serine/Threonine Kinase BRAF: Oncogenic Drivers in Solid Tumors

Roa, P., Bremer, N. V., Foglizzo, V., & Cocco, E. (2024) · Cancers · doi:10.3390/cancers16061215 · Cited by 19 · see citing works

Precision medicine in gynecological cancer (Review)

Aravantinou‐Fatorou, A., GEORGAKOPOULOU, V. E., Dimopoulos, M. A., & Liontos, M. (2025) · Biomedical Reports · doi:10.3892/br.2025.1921 · Cited by 19 · see citing works

Oleanolic acid improved intestinal immune function by activating and potentiating bile acids receptor signaling in E. coli-challenged piglets

Xue, C., Jia, H., Cao, R., Cai, W., Hong, W., Tu, J., Wang, S., Jiang, Q., Bi, C., Shan, A., et al. (2024) · Journal of Animal Science and Biotechnology/Journal of animal science and biotechnology · doi:10.1186/s40104-024-01037-0 · Cited by 20 · see citing works

Past, Present, and Future Therapeutic Strategies for NF-1-Associated Tumors

Na, B. S., Shah, S. R., & Vasudevan, H. N. (2024) · Current Oncology Reports · doi:10.1007/s11912-024-01527-4 · Cited by 18 · see citing works

Advances in chalcone-based anticancer therapy: mechanisms, preclinical advances, and future perspectives

Chowdhary, S., Preeti, P., Shekhar, S., Gupta, N., Kumar, R., & Kumar, V. (2024) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2024.2436908 · Cited by 18 · see citing works

Molecular pathways in reproductive cancers: a focus on prostate and ovarian cancer

Ajayi, A. F., Oyovwi, M. O., Akano, O. P., Akanbi, G. B., & Adisa, F. B. (2025) · Cancer Cell International · doi:10.1186/s12935-025-03658-5 · Cited by 18 · see citing works

Bufalin inhibits hepatocellular carcinoma progression by blocking EGFR-mediated RAS-RAF-MEK-ERK pathway activation

Liu, J., Jiang, J., Huang, J., Fang, Z.-E., Liu, L., Liu, Y., Nian, W., Tang, J., & Wang, Z. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03531-3 · Cited by 20 · see citing works

Ugonin P inhibits lung cancer motility by suppressing DPP-4 expression via promoting the synthesis of miR-130b-5p

Wu, C., Ghule, S. S., Liaw, C., Achudhan, D., Fang, S.-Y., Liu, P., Huang, C., Hsieh, C., & Tang, C. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115483 · Cited by 17 · see citing works

A new strategy of using low-dose caffeic acid carbon nanodots for high resistance to poorly differentiated human papillary thyroid cancer

Xin, J., Song, M., Liu, X., Zou, H., Wang, J., Xiao, L., Jia, Y., Zhang, G., Jiang, W., Lei, M., et al. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02792-y · Cited by 16 · see citing works

SOS1-inspired hydrocarbon-stapled peptide as a pan-Ras inhibitor

Li, A., Li, X., Zou, J., Zhuo, X., Chen, S., Chai, X., Gai, C., Xu, W., Zhao, Q., & Zou, Y. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.106500 · Cited by 16 · see citing works

Recent Perspectives on Cardiovascular Toxicity Associated with Colorectal Cancer Drug Therapy

Kashyap, M. K., Mangrulkar, S. V., Kushwaha, S., Ved, A., Kale, M. B., Wankhede, N. L., Taksande, B. G., Upaganlawar, A., Umekar, M. J., Koppula, S., et al. (2023) · Pharmaceuticals · doi:10.3390/ph16101441 · Cited by 15 · see citing works

Advances in Lipid-Based Nanomedicine: Pathway Specific siRNA Therapy and Optimizing Delivery for Hepatocellular Carcinoma

Thalij, K. M., You, H. W., Aher, K. B., Bhavar, G. B., Kumbhar, S. T., & Habeeb, M. (2025) · International Journal of Nanomedicine · doi:10.2147/ijn.s532246 · Cited by 14 · see citing works

Emerging smart nanocarrier based drug delivery systems for cancer therapeutics

Alam, M. A. (2026) · Next Nanotechnology · doi:10.1016/j.nxnano.2026.100387 · Cited by 14 · see citing works

Mcl-1 Protein and Viral Infections: A Narrative Review

Wyżewski, Z., Stępkowska, J., Kobylińska, A. M., Mielcarska, A., & Mielcarska, M. B. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25021138 · Cited by 14 · see citing works

Novel insights into cardiovascular toxicity of cancer targeted and immune therapies: Beyond ischemia with non-obstructive coronary arteries (INOCA)

Kreidieh, F., & McQuade, J. L. (2024) · American Heart Journal Plus Cardiology Research and Practice · doi:10.1016/j.ahjo.2024.100374 · Cited by 14 · see citing works

Exploring Small-Molecule Inhibitors Targeting MAPK Pathway Components: Focus on ERK, MEK1, and MEK2 Kinases in Cancer Treatment

Mukherjee, T., Mohanty, S., Kaur, J., Das, M., Adhikary, K., Chatterjee, P., & Maiti, R. (2024) · Chemical Biology Letters · doi:10.62110/sciencein.cbl.2024.v11.659 · Cited by 14 · see citing works

Impact of Oncogenic Changes in p53 and KRAS on Macropinocytosis and Ferroptosis in Colon Cancer Cells and Anticancer Efficacy of Niclosamide with Differential Effects on These Two Processes

Nguyen, N. T. H., Sennoune, S. R., Dharmalingam-Nandagopal, G., Sivaprakasam, S., Bhutia, Y. D., & Ganapathy, V. (2024) · Cells · doi:10.3390/cells13110951 · Cited by 14 · see citing works

Ku70 senses cytosolic DNA and assembles a tumor-suppressive signalosome

Pandey, A., Shen, C. X., Feng, S., Tuipulotu, D. E., Ngo, C., Liu, C., Kurera, M., Mathur, A., Venkataraman, S., Zhang, J., et al. (2024) · Science Advances · doi:10.1126/sciadv.adh3409 · Cited by 12 · see citing works

Targeted Therapy Innovations for Melanoma

Amarillo, D., Flaherty, K. T., & Sullivan, R. J. (2024) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2024.05.006 · Cited by 12 · see citing works

A phase Ib study of the combination of naporafenib with rineterkib or trametinib in patients with advanced and metastatic KRAS- or BRAF-mutant non-small cell lung cancer

Planchard, D., Wolf, J., Solomon, B., Sebastian, M., Wermke, M., Heist, R. S., Sun, J., Kim, T. M., Reguart, N., Sanmamed, M. F., et al. (2024) · Lung Cancer · doi:10.1016/j.lungcan.2024.107964 · Cited by 12 · see citing works

Insights into curcumin’s anticancer activity in pancreatic ductal adenocarcinoma: Experimental and computational evidence targeting HRAS, CCND1, EGFR and AKT1

Cao, J., Zhang, X., Xia, Q., Hang, K., Men, J., Tian, J., Liao, D., Xia, Z., & Li, K. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.108264 · Cited by 12 · see citing works

Host-derived growth factors drive ERK phosphorylation and MCL1 expression to promote osteosarcoma cell survival during metastatic lung colonization

McAloney, C. A., Makkawi, R., Budhathoki, Y., Cannon, M. V., Franz, E., Gross, A. C., Cam, M., Vetter, T. A., Duhen, R., Davies, A. E., et al. (2023) · Cellular Oncology · doi:10.1007/s13402-023-00867-w · Cited by 12 · see citing works

Practical immunomodulatory landscape of glioblastoma multiforme (GBM) therapy

Norollahi, S. E., Yousefi, B., Nejatifar, F., Yousefzadeh-Chabok, S., Rashidy‐Pour, A., & Samadani, A. A. (2024) · Journal of the Egyptian National Cancer Institute · doi:10.1186/s43046-024-00240-4 · Cited by 11 · see citing works

Extracellular vesicles in atherosclerosis cardiovascular disease: emerging roles and mechanisms

Deng, H., Qiu, W., Zhang, Y., & Hua, J. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1611557 · Cited by 11 · see citing works

Molecularly Targeted Therapies in Oncology: Mechanisms, Resistance, and Combination Strategies

Giercuszkiewicz-Haśnik, K., MORAK-MŁODAWSKA, B. I., & Jeleń, M. (2026) · Molecules · doi:10.3390/molecules31071195 · Cited by 11 · see citing works

6-Gingerol Induced Apoptosis and Cell Cycle Arrest in Glioma Cells via MnSOD and ERK Phosphorylation Modulation

Lim, S.-W., Chen, W., Ko, H.-J., Su, Y., Wu, C., Huang, F.-L., Li, C., & Tsai, C.-Y. (2024) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2024.084 · Cited by 10 · see citing works

UCHL3: a crucial deubiquitinase in DNA damage repair and tumor progression

Liu, J., Hu, S., Xiao, J., & Zhou, J. (2025) · Cancer Cell International · doi:10.1186/s12935-025-03884-x · Cited by 10 · see citing works

KRAS mutations in non-small cell lung cancer: Translational aspects, current therapies and challenges for future research

Colombino, M., Palomba, G., Casula, M., Pisano, M., Tore, S., Serra, R., Putzu, C., Fadda, G. M., Maestrale, G. B., Casula, S., et al. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104925 · Cited by 10 · see citing works

Cytotoxic effect of crotoxin on cancer cells and its antitumoral effects correlated to tumor microenvironment: A review

Almeida, T. C., Silva, L. D. M. R., de Oliveira, A. M. B., Lopes, F. S. R., Sant’Anna, M. B., & Picolo, G. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.124892 · Cited by 10 · see citing works

Broad Next-Generation Integrated Sequencing of Myelofibrosis Identifies Disease-Specific and Age-Related Genomic Alterations

Kandarpa, M., Robinson, D. R., Wu, Y., Qin, T., Pettit, K. M., Li, Q., Luker, G. D., Sartor, M. A., Chinnaiyan, A. M., & Talpaz, M. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0372 · Cited by 9 · see citing works

Structure-Guided Discovery and Preclinical Assessment of Novel (Thiophen-3-yl)aminopyrimidine Derivatives as Potent ERK1/2 Inhibitors

Wen, S., Xiao, H., Yang, P., Zhang, Y., Bu, F., Wu, Y., Sun, Q., Wang, G., & Ouyang, L. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c02392 · Cited by 9 · see citing works

Complement Factor B (CFB) inhibits the malignant progression of lung adenocarcinoma by downregulating the Ras/MAPK signaling pathway

He, C., Wang, X., Jiang, B., Zhu, M., Zhang, H., Duan, Y., & Li, Y. (2024) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2024.110130 · Cited by 9 · see citing works

Metal-based antibody, nanobody, and peptide conjugates: Potential for breast cancer therapy

Kaya, B., Laurencia, D., Ayoub, M. F., Azad, M. G., Dharmasivam, M., & Richardson, D. R. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100087 · Cited by 9 · see citing works

Beyond Detection: Conventional and Emerging Biomarkers in Gastrointestinal Cancers

Han, D. M., Wakefield, M. R., & Fang, Y. (2025) · Cancers · doi:10.3390/cancers17172725 · Cited by 10 · see citing works

Colorectal cancer pathogenesis, oncogenic signaling networks and targeted therapeutic advances

Chen, Y., Zhang, J., Ding, Y., Zhu, F., & Chen, Y. (2026) · Molecular Biomedicine · doi:10.1186/s43556-026-00433-4 · Cited by 11 · see citing works

Targeting Breast Cancer: The Familiar, the Emerging, and the Uncharted Territories

Aliabadi, H. M., Manda, A., Sidgal, R., & Chung, C. (2023) · Biomolecules · doi:10.3390/biom13091306 · Cited by 9 · see citing works

MicroRNA miR-212-5p Regulates the MEK/ERK Signaling Pathway by Targeting A-Raf proto-oncogene serine/threonine-protein kinase (ARAF) to Regulate Cowshed PM2.5-Induced NR8383 Apoptosis

Sun, K., Sun, Y., Jia, Y., Duan, X., Ma, Z., Zhang, X., Wang, L., Zhu, Y., Gao, Y., & Basang, W. (2023) · Toxics · doi:10.3390/toxics11120981 · Cited by 9 · see citing works

The effects of the combination therapy of chemotherapy drugs on the fluctuations of genes involved in the TLR signaling pathway in glioblastoma multiforme therapy

Norollahi, S. E., Yousefzadeh-Chabok, S., Yousefi, B., Nejatifar, F., Rashidy‐Pour, A., & Samadani, A. A. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117137 · Cited by 8 · see citing works

Exercise training-driven exosomal miRNA-323–5p activity suppresses adipogenic conversion of 3T3-L1 cells via the DUSP3/ERK pathway

Osawa, S., Kato, H., Kemmoku, D., Yamaguchi, S., Jiang, L., Tsuchiya, Y., Takakura, H., & Izawa, T. (2024) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2024.150447 · Cited by 8 · see citing works

Proteomic and phosphoproteomic signatures of aging mouse liver

Mohallem, R., Schaser, A. J., & Aryal, U. K. (2025) · GeroScience · doi:10.1007/s11357-025-01601-0 · Cited by 8 · see citing works

Natural products as kinase inhibitors in lung cancer: molecular mechanisms, therapeutic potential, and clinical trials

Wali, A. F., Talath, S., Babiker, R., El‐Tanani, M., Rangraze, I. R., Ibraheem, W., Al-Dhaheri, Y., Satyam, S. M., & El‐Tanani, Y. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1764550 · Cited by 8 · see citing works

Recent progress and the emerging role of lncRNAs in cancer drug resistance; focusing on signaling pathways

Saadh, M. J., Rasulova, I., Almoyad, M. A. A., Kiasari, B. A., Ali, R. T., Rasheed, T., Faisal, A., Hussain, F., Jawad, M. J., Hani, T., et al. (2023) · Pathology - Research and Practice · doi:10.1016/j.prp.2023.154999 · Cited by 8 · see citing works

Association Between RAS/BRAF Mutations and Complete Response Following Total Neoadjuvant Therapy in Patients with Rectal Cancer: A Prospective Multicentered Study

Bedrikovetski, S., Traeger, L., Fitzsimmons, T. R., Price, T. J., Ruszkiewicz, A. R., Vather, R., & Sammour, T. (2023) · Annals of Surgical Oncology · doi:10.1245/s10434-023-14722-7 · Cited by 8 · see citing works

New LPA1 receptor modulators: Design, synthesis, in-silico, and anticancer studies of triazole and oxadiazole analogs

Bhagyalalitha, M., Pavan, S. R., Prabhu, A., Akshatha, H. S., Sethu, A. K., Singh, M., Pujar, K. G., Revana Siddappa, B. C., Bidye, D. P., & Pujar, G. V. (2023) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2023.136672 · Cited by 8 · see citing works

Urolithin A Targets Both PI3K/p-AKT/mTOR and p-c-RAF/MEK/p-ERK Signaling Pathways in Colorectal Cancer

El‐Wetidy, M. S., Helal, H., & Rady, M. I. (2024) · Egyptian Academic Journal of Biological Sciences. C, Physiology and Molecular Biology/Egyptian Academic Journal of Biological Sciences. C, Physiology and Molecular Biology · doi:10.21608/eajbsc.2024.355267 · Cited by 7 · see citing works

Overcoming multiple barriers to deliver photo-gene system for glioma-targeted combined therapy

Qin, Y., Yang, L., Yang, Y., Gao, W., Aihemaiti, K., Jiang, G., Huang, R., Khan, H., & Huang, R. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.10.024 · Cited by 7 · see citing works

Metabolic and Regulatory Pathways Involved in the Anticancer Activity of Perillyl Alcohol: A Scoping Review of In Vitro Studies

Brochado, A. C. B., de Moraes, J. A., de Oliveira, B. R., Lima, V. H. D. S., Mariano, E. D., Karande, S., Romasco, T., Leite, P. E. C., Mourão, C. F., & Alves, G. G. (2024) · Cancers · doi:10.3390/cancers16234003 · Cited by 8 · see citing works

Therapeutic approach for triple-negative breast Cancer through poly (ADP-ribose) Polymerase-1 inhibitors: Current update

Das, A., Mandal, S. K., Arya, S., Samanta, S. K., Kumar, A., Panchpuri, M., Abdel‐Gawad, H., Dwibedi, V., Das, N., Bose, S., et al. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.108558 · Cited by 7 · see citing works

Metabolomics and integrated network pharmacology analysis revealed multi-targeted anti-cancer effect of FuZhengXiaoJi decoction against non-small cell lung cancer

Jiang, X., Xu, Z., Wang, H., Zhao, J., Maihemuti, N., Jiang, S., Xiao, M., Zhang, K., Liang, S., Shi, Y., et al. (2025) · Phytomedicine · doi:10.1016/j.phymed.2025.156855 · Cited by 7 · see citing works

Molecular targeted therapies for cutaneous squamous cell carcinoma: recent developments and clinical implications

Singh, H. B., Chopra, H., Singh, I., Mohanto, S., Ahmed, M. G., Ghumra, S., Seelan, A., Survase, M., Kumar, A., Mishra, A., et al. (2023) · EXCLI journal · doi:10.17179/excli2023-6489 · Cited by 7 · see citing works

MAGI3 enhances sensitivity to sunitinib in renal cell carcinoma by suppressing the MAS/ERK axis and serves as a prognostic marker

Wang, H., Chen, Y., Yang, Y., Song, R., Gu, S., Cao, X., Zhang, L., Yang, Y., Hou, T., Qi, X., et al. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-07427-0 · Cited by 7 · see citing works

HER3 in breast cancer: molecular insights, clinical implications, and therapeutic horizons

Ergün, Y. (2025) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2025.2540355 · Cited by 6 · see citing works

Interactions between LncRNAs and MAPK signaling pathways in the pathogenesis of breast cancer

Ding, B., Wang, X., Zhang, Z., Wang, Y., Bo, W., Zhang, M., Tian, Z., Wang, Y., Xue, X., & Zhang, M. (2025) · Cancer Cell International · doi:10.1186/s12935-025-03943-3 · Cited by 6 · see citing works

TAGLN2 targeted control of ARPC5-mediated activation of the MEK/ERK signaling pathway influences the proliferation, invasion, and metastasis of pancreatic cancer cells

Gao, Y., Hou, J., Fei, X., Ren, L., Lu, R., Liu, P., Liu, S., Zhu, C., Wang, X., & Pan, Y. (2024) · Cellular Signalling · doi:10.1016/j.cellsig.2024.111227 · Cited by 6 · see citing works

Plasma-Activated Medium Inhibited the Proliferation and Migration of Non-Small Cell Lung Cancer A549 Cells in 3D Culture

Sun, Z., Ding, C., Wang, Y., Lu, T., & Song, W. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252413262 · Cited by 7 · see citing works

Predicting the Progression from Asymptomatic to Symptomatic Multiple Myeloma and Stage Classification Using Gene Expression Data

Karathanasis, N., & Spyrou, G. M. (2025) · Cancers · doi:10.3390/cancers17020332 · Cited by 6 · see citing works

Untangling sporadic brain arteriovenous malformations: towards targeting the KRAS/MAPK pathway

Jabarkheel, R., Li, L., Frankfurter, M., Zhang, D. Y., Gajjar, A. A., Muhammad, N., Srinivasan, V. M., Burkhardt, J., & Kahn, M. L. (2024) · Frontiers in Surgery · doi:10.3389/fsurg.2024.1504612 · Cited by 5 · see citing works

A Review on EGFR-Tyrosine Kinase Inhibitors and their Resistance Mechanisms

Naim, M. J., & Samad, A. (2025) · Current Pharmaceutical Design · doi:10.2174/0113816128349342250121053445 · Cited by 5 · see citing works

CREPT promotes LUAD progression by enhancing the CDK9 and RNAPII assembly to promote ERK-driven gene transcription

Li, M., Lin, Y.-T., Wang, J., He, Y., Ma, D., Tian, Y., Wang, Y., Liu, Y., Farooq, U., Wang, Y., et al. (2025) · Theranostics · doi:10.7150/thno.115572 · Cited by 5 · see citing works

Pathway-Specific Therapeutic Modulation of Melanoma: Small-Molecule Inhibition of BRAF–MEK and KIT Signaling in Contemporary Precision Oncology with a Special Focus on Vemurafenib, Trametinib, and Imatinib

Kawczak, P., & Bączek, T. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14227906 · Cited by 5 · see citing works

Acute myeloid leukemia drug resistance: targetable nodes and the clinical trajectory of small-molecule inhibitors

Zhang, X., Peng, Y., Tian, Y., Chen, S., Jia, Y., Liu, M., & Li, Z. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1696229 · Cited by 5 · see citing works

RAF1 facilitates KIT signaling and serves as a potential treatment target for gastrointestinal stromal tumor

Zhang, L., Zhang, S., Cao, X., Shi, J., Zhao, S., Tian, J., Xiao, K., Wang, M., Liu, J., Wang, C., et al. (2024) · Oncogene · doi:10.1038/s41388-024-03063-8 · Cited by 5 · see citing works

Emerging role of MAPK signaling in glycosphingolipid-associated tumorigenesis

Khamrui, E., Banerjee, S., Mukherjee, D. D., & Biswas, K. (2024) · Glycoconjugate Journal · doi:10.1007/s10719-024-10168-5 · Cited by 5 · see citing works

Targeting chaperone modifications: Innovative approaches to cancer treatment

Stewart, M. S., & Schisler, J. C. (2024) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2024.107907 · Cited by 5 · see citing works

Sorafenib-Loaded Silica-Containing Redox Nanoparticle Decreases Tumorigenic Potential of Lewis Lung Carcinoma

Shashni, B., Tran, H. T., Vong, L. B., Chung, R., & Nagasaki, Y. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17010050 · Cited by 5 · see citing works

Inhibiting synovial inflammation and promoting cartilage repair in rheumatoid arthritis using a matrix metalloproteinase-binding hydrogel

Xue, Z., Li, N., Du, K., Shu, J., Huang, Z., Gao, Z., Xie, X., Li, Q., & Lu, Y. (2025) · Materials Today Bio · doi:10.1016/j.mtbio.2025.101792 · Cited by 5 · see citing works

Multifaceted Biological Spectra of Tandyukisin Against Breast Cancer: Targeting ERBB2 Signaling and Beyond

Chand, J., Fanai, H. L., Ahmad, S. F., Al‐Mazroua, H. A., & Emran, T. B. (2025) · Peptide Science · doi:10.1002/pep2.70005 · Cited by 5 · see citing works

Clinical research progress on BRAF V600E-mutant advanced colorectal cancer

Zeng, C., Wang, M., Xie, S., Wang, N., Wang, Z., Yi, D., Kong, F., & Chen, L. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-05301-0 · Cited by 5 · see citing works

Erbin: an important therapeutic target for blocking tumor metastasis

Qiu, T., Tan, L., Yan, J., & Luo, Q. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1474798 · Cited by 4 · see citing works

Discovery of Novel Aromatic Urea-Imidazole Salt Derivatives for Cancer Therapy via Targeting ERK1/2

Wang, M., Yang, S., Li, X., Zheng, Y., Bai, Y., Luo, W., Zhu, G., Chang, J., & Zhu, B. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01434 · Cited by 5 · see citing works

Genomic and immunogenomic profiling of extramedullary acute myeloid leukemia reveals actionable clonal branching and frequent immune editing

Collignon, C., Hansen, T. H., Hercus, C., Ruzinova, M. B., Guépin, G. R., Bonmati, C., Rubio, M., Feugier, P., Gaudfrin, M., Sartelet, H., et al. (2025) · Blood Cancer Journal · doi:10.1038/s41408-025-01345-2 · Cited by 4 · see citing works

Targeting the MAPK–RAS–RAF signaling pathway in cancer therapy

Santarpia, L., Lippman, S. M., & El‐Naggar, A. K. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.645805 · Cited by 1,032 · see citing works

Targeting RAS–ERK signalling in cancer: promises and challenges

Samatar, A. A., & Poulikakos, P. I. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4281 · Cited by 1,163 · see citing works

Targeting the Raf-MEK-ERK Mitogen-Activated Protein Kinase Cascade for the Treatment of RAS Mutant Cancers

Hayes, T. K., & Der, C. J. (2014) · Springer eBooks · doi:10.1007/978-3-7091-1806-1_6 · Cited by 5 · see citing works

Targeting the RAF–MEK–ERK pathway in cancer therapy

Montagut, C. O., & Settleman, J. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.01.022 · Cited by 466 · see citing works

Stamping out RAF and MEK1/2 to inhibit the ERK1/2 pathway: an emerging threat to anticancer therapy

Mandal, R., Becker, S., & Strebhardt, K. (2016) · Oncogene · doi:10.1038/onc.2015.329 · Cited by 89 · see citing works